Skip to main content
Clinical Trials/ISRCTN93280043
ISRCTN93280043
Completed
Not Applicable

A randomised controlled trial to evaluate whether a short course of once weekly risedronate prevents bone loss following high-dose steroid therapy for an acute exacerbation of inflammatory bowel disease

niversity Hospitals Bristol NHS Foundation Trust (UK)0 sites100 target enrollmentNovember 20, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Inflammatory bowel disease (ulcerative colitis and Crohn's disease)
Sponsor
niversity Hospitals Bristol NHS Foundation Trust (UK)
Enrollment
100
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 20, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity Hospitals Bristol NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged greater than or equal to 16 years, either sex
  • 2\. Ulcerative colitis and Crohn's disease
  • 3\. Experiencing a relapse
  • 4\. Requiring steroid therapy

Exclusion Criteria

  • 1\. Aged under 16 years
  • 2\. Use of corticosteroids in the preceding 3 months
  • 3\. Evidence of osteoporosis (known vertebral fracture, T score less than \-2\.5\)
  • 4\. Pregnant and lactating women
  • 5\. Women of childbearing age will be eligible provided they use reliable contraception
  • 6\. Bone active therapy within previous 12 months (excluding calcium and low dose vitamin D)
  • 7\. Previous treatment with a bisphosphonate at any time
  • 8\. Associated disorder which may influence bone metabolism
  • 9\. Lactose intolerance

Outcomes

Primary Outcomes

Not specified

Similar Trials